Cryptococcal antigen screening and targeted pre-emptive therapy in patients initiating ART: a prospective cohort study. (360G-Wellcome-096190_Z_11_Z)
Cryptococcal meningitis is a leading cause of death in HIV-infected patients in the developing world. Many patients continue to present late for antiretroviral treatment (ART), and many die just before and after starting therapy. Cryptococcal meningitis causes many of these early deaths. However, many cases of cryptococcal meningitis may be preventable. Routine screening for serum cryptococcal antigen (CRAG), indicating sub-clinical infection, can identify the 10% of patients with CD4+ cells
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 386695 |
| Applicant Surname | Longley |
| Approval Committee | International Interview Committee |
| Award Date | 2011-06-14T00:00:00+00:00 |
| Financial Year | 2010/11 |
| Grant Programme: Title | Research Training Fellowship |
| Internal ID | 096190/Z/11/Z |
| Lead Applicant | Dr Nicola Longley |
| Partnership Value | 386695 |
| Planned Dates: End Date | 2016-07-01T00:00:00+00:00 |
| Planned Dates: Start Date | 2011-08-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |
| Sponsor(s) | Prof Thomas Harrison |